Related Experiment Video
Updated: Jul 23, 2025
Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment
Published on: January 12, 2024
Research interest in the usage of dupilumab for atopic dermatitis: a bibliometric analysis
1Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China, Department of Dermatology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Background:
Recently, dupilumab has been used for the treatment of atopic dermatitis (AD), and growing interest in the subject has resulted in an increasing number of publications.
Objectives:
Our study aimed to evaluate the rapid progress, identify hot topics, and explore scientific advances and future trends in this field.
Materials & Methods:
The global distribution of publications was estimated with no time restrictions. Dupilumab as a treatment for AD was scanned in the Web of Science core collection using the topic terms "dupilumab" and "atopic Dermatitis". VOSviewer was applied for visualization of bibliometric analysis. Analysis of country and region distribution, impact of journal, authors, population, economic estimation among countries and regions, key words, as well as the top 20 cited articles were performed.
Results:
In total, 910 publications were yielded from the Web of Science core collection database. Most studies were published in the USA (46.15%), Germany (17.91%), and France (14.07%); other countries included Denmark, the Netherlands, and Canada based on normalization of article numbers according to population and economic evaluation. Studies were most frequently reported in the British Journal of Dermatology and the Journal of the American Academy of Dermatology. Pirozzi, G. from France was the top-cited author. The most frequent key words were concepts in dermatology, allergy, and immunology. Remarkable landmark clinical trials were noted in the top 20 cited publications.
Conclusion:
The research of dupilumab for AD is rapidly developing. Countries in North America and Europe have remarkably contributed to researches of dupilumab as a treatment for AD. The bibliometric analysis also presents hallmark publications reporting scientific advances in therapy progress, which may provide a foundation for further research.
